PT-112: FDA Clears Phase 3 Trial of Novel Therapy for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPembrolizumab Plus Enzalutamide Therapy Shows No Benefit in Metastatic Castration-Resistant Prostate Cancer Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxUPDATE: JANX007 Starts Phase 1b Expansion Studies
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNTS071 to Target p53 Y220C Mutation in Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxSetback in Prostate Cancer Trial: CAPItello-280 Study for Truqap Discontinued
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Trial: APG-5918 an EED Inhibitor for Prostate Cancer Therapy
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: CTS2190 Targets Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial: SYN818 Shows Promise for Prostate Cancer Patients With HRR Genetic Mutations
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: NXP900 for Overcoming Resistance in Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare antibody-drug conjugate apalutamide artificial intelligence ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- UPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent June 12, 2025
- Sn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials June 11, 2025
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025